Defunct Company
Total Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
412
NCT01206335
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2010
Completion: Feb 28, 2013
NCT01678963
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Start: Nov 30, 2012
Completion: Mar 31, 2015
NCT02614937
Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
Phase: Phase 1/2
Start: Apr 30, 2013
Completion: Dec 31, 2014
NCT02349516
Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)
Role: Collaborator
Start: Feb 28, 2015
Completion: Sep 30, 2015
NCT02511613
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
Start: Jul 31, 2015
Completion: Apr 30, 2016
NCT02727881
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
Phase: Phase 3
Start: Apr 12, 2016
Completion: Dec 31, 2017